A Phase II, Multicenter, Double Blind, Double Dummy, Randomized, 2 Arms Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
Latest Information Update: 07 Aug 2023
At a glance
- Drugs CHF 6563 (Primary) ; Morphine
- Indications Opioid-related disorders
- Focus Adverse reactions
- Acronyms NOWSHINE
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 01 Feb 2021 Planned End Date changed from 30 Jan 2021 to 1 Jan 2024.
- 01 Feb 2021 Planned primary completion date changed from 14 Nov 2020 to 1 Sep 2023.
- 01 Feb 2021 Status changed to recruiting.